Jun Tanaka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jun Tanaka has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Takashi Nakae
Central Research Laboratory, Japan Blood Products Organization, Kobe, Japan; Research Center for Anti-infectious Drugs, Kitasato University, Tokyo, Japan
3 shared publicationsAkihito Kamizono
Central Research Laboratory, Japan Blood Products Organization, Kobe, Japan
2 shared publicationsAtsushi Nakano
Central Research Laboratory, Japan Blood Products Organization, Kobe, Japan
2 shared publicationsYasuo Ono
Teikyo University
2 shared publicationsA. P. Koo
Department of Rheumatic and Immunologic Disease, The Cleveland Clinic Foundation, Cleveland, Ohio
1 shared publicationAkira Kitashoji
Central Research Laboratory, Japan Blood Products Organization, Kobe, Japan
1 shared publication
Latest Publications
- Open Access
- 24 August 2021
- Published by Springer Nature in Research Square
Intravenous Immunoglobulin Suppresses Chemotherapy-induced Peripheral Neurotoxicity via Macrophage Modulation in Rats and Mice
Chemotherapy-induced peripheral neurotoxicity (CIPN) is a serious adverse effect that leads to treatment discontinuation by patients receiving anticancer therapy. Treatment discontinuation is a serious and life-threatening problem for patients with cancer; hence, there is a need for drugs that suppress the induction of CIPN by anticancer drugs. Intravenous immunoglobulin (IVIg) reportedly suppresses bortezomib-induced CIPN in a rat model. Here, using rodent models, we showed that IVIg can also suppress peripheral neurotoxicity induced by anticancer drugs other than bortezomib. Furthermore, the suppressive effect of IVIg disappeared when macrophages were depleted. These findings indicate two novel independent possibilities of alleviating CIPN using IVIg. First, CIPN can be controlled by macrophage modulation. Second, IVIg directly combined with anti-cancer drugs can avoid restrictions on the use of anti-cancer drugs due to CIPN inductions. However, further research is necessary for the bench-to-bedside translation of these novel applications of IVIg. Our findings lay a strong foundation for research on IVIg therapeutics.
- 24 August 2021
- Published by Springer Nature in Research Square
Open AccessIntravenous Immunoglobulin Suppresses Chemotherapy-induced Peripheral Neurotoxicity via Macrophage Modulation in Rats and Mice
Chemotherapy-induced peripheral neurotoxicity (CIPN) is a serious adverse effect that leads to treatment discontinuation by patients receiving anticancer therapy. Treatment discontinuation is a serious and life-threatening problem for patients with cancer; hence, there is a need for drugs that suppress the induction of CIPN by anticancer drugs. Intravenous immunoglobulin (IVIg) reportedly suppresses bortezomib-induced CIPN in a rat model. Here, using rodent models, we showed that IVIg can also suppress peripheral neurotoxicity induced by anticancer drugs other than bortezomib. Furthermore, the suppressive effect of IVIg disappeared when macrophages were depleted. These findings indicate two novel independent possibilities of alleviating CIPN using IVIg. First, CIPN can be controlled by macrophage modulation. Second, IVIg directly combined with anti-cancer drugs can avoid restrictions on the use of anti-cancer drugs due to CIPN inductions. However, further research is necessary for the bench-to-bedside translation of these novel applications of IVIg. Our findings lay a strong foundation for research on IVIg therapeutics.
- Open Access
- 1 May 2018
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 24 (5) , 383-388
Effective concentration of intravenous immunoglobulin for neutralizing Panton-Valentine leukocidin in human blood
- 1 May 2018
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 24 (5) , 383-388
Open AccessEffective concentration of intravenous immunoglobulin for neutralizing Panton-Valentine leukocidin in human blood
- Open Access
- 22 June 2016
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 95 (2) , 37
Intravenous Immunoglobulin Suppresses Abortion Relates to an Increase in the CD44bright NK Subset in Recurrent Pregnancy Loss Model Mice
Recurrent pregnancy loss (RPL), which mostly is of unknown etiology ("unexplained RPL," uRPL), is defined as three or more consecutive spontaneous abortions. Some women with uRPL display a higher fraction and cytotoxicity of natural killer (NK) cells in the periphery and endometrium. Therefore, some uRPL cases have been explained by autoimmune abnormalities. The efficacy of intravenous immunoglobulin (IVIg) for uRPL has been confirmed in several clinical trials; however, its mechanism remains unknown, mainly because the abortion mechanism remains to be elucidated. In the present study, we analyzed the mechanisms of both abortion and IVIg action using an uRPL mouse model in which abortion was induced by lipopolysaccharide (LPS) injection. IVIg attenuated the abortion rate of uRPL model mice. And the suppressive effect of IVIg was maximized by high dose administration at early phase after LPS injection. Specifically, we discovered the presence of two distinct uterine NK (uNK) subsets: CD44bright and CD44mid. In uRPL model mice, we observed an increase in the number of CD44bright uNK cells, while the CD44mid uNK subset remained unchanged. Furthermore, when abortion was reduced by IVIg administration, the cell number of the CD44bright uNK subset did not increase, which might allow differentiating pathological from normal uNK cells based on CD44 expression. Based on these results, we propose not only an effective administration protocol of IVIg to the uRPL model mice, but also a novel mechanism of abortion related to the increase in the CD44bright subset and of IVIg, which suppresses the increase of the CD44bright subset.
- 22 June 2016
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 95 (2) , 37
Open AccessIntravenous Immunoglobulin Suppresses Abortion Relates to an Increase in the CD44bright NK Subset in Recurrent Pregnancy Loss Model Mice
Recurrent pregnancy loss (RPL), which mostly is of unknown etiology ("unexplained RPL," uRPL), is defined as three or more consecutive spontaneous abortions. Some women with uRPL display a higher fraction and cytotoxicity of natural killer (NK) cells in the periphery and endometrium. Therefore, some uRPL cases have been explained by autoimmune abnormalities. The efficacy of intravenous immunoglobulin (IVIg) for uRPL has been confirmed in several clinical trials; however, its mechanism remains unknown, mainly because the abortion mechanism remains to be elucidated. In the present study, we analyzed the mechanisms of both abortion and IVIg action using an uRPL mouse model in which abortion was induced by lipopolysaccharide (LPS) injection. IVIg attenuated the abortion rate of uRPL model mice. And the suppressive effect of IVIg was maximized by high dose administration at early phase after LPS injection. Specifically, we discovered the presence of two distinct uterine NK (uNK) subsets: CD44bright and CD44mid. In uRPL model mice, we observed an increase in the number of CD44bright uNK cells, while the CD44mid uNK subset remained unchanged. Furthermore, when abortion was reduced by IVIg administration, the cell number of the CD44bright uNK subset did not increase, which might allow differentiating pathological from normal uNK cells based on CD44 expression. Based on these results, we propose not only an effective administration protocol of IVIg to the uRPL model mice, but also a novel mechanism of abortion related to the increase in the CD44bright subset and of IVIg, which suppresses the increase of the CD44bright subset.
- 1 January 2014
- Published by Japanese Society of Inflammation and Regeneration in Inflammation and Regeneration
- Vol. 34 (3) , 134-139
Intravenous immunoglobulin suppresses B cell activities via antigen recognition region
- 1 January 2014
- Published by Japanese Society of Inflammation and Regeneration in Inflammation and Regeneration
- Vol. 34 (3) , 134-139
Intravenous immunoglobulin suppresses B cell activities via antigen recognition region
- 1 March 2012
- Published by Elsevier in Cell Metabolism
- Vol. 15 (3) , 372-381
FoxOs Integrate Pleiotropic Actions of Insulin in Vascular Endothelium to Protect Mice from Atherosclerosis
- 1 March 2012
- Published by Elsevier in Cell Metabolism
- Vol. 15 (3) , 372-381
FoxOs Integrate Pleiotropic Actions of Insulin in Vascular Endothelium to Protect Mice from Atherosclerosis
- 1 December 2008
- Vol. 61 (6) , 379-87
Complement-mediated bactericidal effect of antibodies in human intravenous preparation against multi-drug resistant pseudomonas aeruginosa.
After incubation of four of ten strains of multi-drug resistant Pseudomonas aeruginosa (MDRP) with the healthy human serum for one hour, the bacteria lysed and the viable cell count decreased with the disappearance of the C3 complement. Over 99% of IgG was deleted from the serum by passing the serum through a Protein G Sepharose column. In such IgG-deleted serum, the bactericidal activity on P. aeruginosa was cancelled. The bactericidal activity recovered by adding human intravenous immunoglobulin preparation (IVIG) at the concentration of 2-4 mg/mL to the serum. Moreover, a strong bactericidal activity was shown in the case of some strains that the antibody titers of IVIG were high. It was thought that specific antibodies to some of P aeruginosa are contained in IVIG and activated the classical pathway of complement system; as a result, the bacterial lyses had been caused. Sera from healthy persons contain antibodies to P aeruginosa as well as complement components. Since the complement-mediated bactericidal activity disappeared by removing IgG in this study. These results suggest that the IVIG therapy in bacterial infections is expected to recover the immune function so as complement-mediated bactericidal activity as well as opsonic activity against P aeruginosa, especially in the patient with neutropenia.
- 1 December 2008
- Vol. 61 (6) , 379-87
Complement-mediated bactericidal effect of antibodies in human intravenous preparation against multi-drug resistant pseudomonas aeruginosa.
After incubation of four of ten strains of multi-drug resistant Pseudomonas aeruginosa (MDRP) with the healthy human serum for one hour, the bacteria lysed and the viable cell count decreased with the disappearance of the C3 complement. Over 99% of IgG was deleted from the serum by passing the serum through a Protein G Sepharose column. In such IgG-deleted serum, the bactericidal activity on P. aeruginosa was cancelled. The bactericidal activity recovered by adding human intravenous immunoglobulin preparation (IVIG) at the concentration of 2-4 mg/mL to the serum. Moreover, a strong bactericidal activity was shown in the case of some strains that the antibody titers of IVIG were high. It was thought that specific antibodies to some of P aeruginosa are contained in IVIG and activated the classical pathway of complement system; as a result, the bacterial lyses had been caused. Sera from healthy persons contain antibodies to P aeruginosa as well as complement components. Since the complement-mediated bactericidal activity disappeared by removing IgG in this study. These results suggest that the IVIG therapy in bacterial infections is expected to recover the immune function so as complement-mediated bactericidal activity as well as opsonic activity against P aeruginosa, especially in the patient with neutropenia.
- 1 January 1994
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 9 (4) , 210-215
Defective leukocyte function-related cryoprecipitable protein in Cryoglobulinemia
Cryoprecipitable proteins (CPP), purified from plasmas removed during plasmapheresis treatment of patients with type II and type III cryoglobulinemia (CG), were evaluated in vitro for their effect on normal leukocyte function. CPP reduced normal mononuclear cell blastogenesis and polymorphonuclear cell phagocytosis responses in a dose‐dependent fashion. At the maximum concentration studied, 5,000 (μg/ml, CPP were shown to suppress normal blastogenesis and phagocytosis 30–60% and 50–80% below the albumin control, respectively. A 50% suppression of normal blastogenesis and phagocytosis was observed at 500 p.g/ml for type III CPP. Leukocyte functions in CG patients were evaluated and compared to those of healthy controls. Blastogenesis and phagocytosis were significantly inhibited in CG patients. These studies suggest that CG patients have defective leukocyte function and that CPP have suppressive effects on normal leukocyte function. Our studies suggest that removal of CPP in CG patients may prove beneficial not only in reducing typical symptoms of CG but also in reducing the potencial inhibitory effects of CPP on leukocyte function.
- 1 January 1994
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 9 (4) , 210-215
Defective leukocyte function-related cryoprecipitable protein in Cryoglobulinemia
Cryoprecipitable proteins (CPP), purified from plasmas removed during plasmapheresis treatment of patients with type II and type III cryoglobulinemia (CG), were evaluated in vitro for their effect on normal leukocyte function. CPP reduced normal mononuclear cell blastogenesis and polymorphonuclear cell phagocytosis responses in a dose‐dependent fashion. At the maximum concentration studied, 5,000 (μg/ml, CPP were shown to suppress normal blastogenesis and phagocytosis 30–60% and 50–80% below the albumin control, respectively. A 50% suppression of normal blastogenesis and phagocytosis was observed at 500 p.g/ml for type III CPP. Leukocyte functions in CG patients were evaluated and compared to those of healthy controls. Blastogenesis and phagocytosis were significantly inhibited in CG patients. These studies suggest that CG patients have defective leukocyte function and that CPP have suppressive effects on normal leukocyte function. Our studies suggest that removal of CPP in CG patients may prove beneficial not only in reducing typical symptoms of CG but also in reducing the potencial inhibitory effects of CPP on leukocyte function.